Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study

BACKGROUND: Although trastuzumab (T) represents the standard of care for the adjuvant treatment of HER2‐positive early‐stage breast cancer, contrasting results are available about the cardiac toxicity associated to its use. We conducted a multiregional population‐based cohort investigation aimed to...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Franchi, Matteo, Trama, Annalisa, Merlo, Ivan, Minicozzi, Pamela, Tarantini, Luigi, Garau, Donatella, Kirchmayer, Ursula, Di Martino, Mirko, Romero, Marilena, De Carlo, Ilenia, Scondotto, Salvatore, Apolone, Giovanni, Corrao, Giovanni
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2020
Gaiak:
Breast Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543336/
https://ncbi.nlm.nih.gov/pubmed/32770690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0216
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak